Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Target price


17.04.24 / Tradegate WKN: A0MKPR / Name: Cellectis / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Cellectis Nom. Stock

Cellectis Nom. dominated the market today, gaining €0.090 (3.970%).
For the coming years our community has positive and negative things to say abot the Cellectis Nom. stock. Criterium "Company culture" gathered the most positive votes but regarding "Worthwhile Investment for the next years" there were negative voices in the community.

Pros and Cons of Cellectis Nom. in the next few years

S********** s********
G***** c******* t* c**********
W********* I********* f** t** n*** y****
C******** o* t** e**********
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Cellectis Nom. vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Cellectis Nom. 3.970% -12.429% -0.726% 21.664% -19.772% -85.727% -
Valneva SE 0.050% -4.767% 5.029% -28.287% -22.919% -70.987% 5.481%
Nanobiotix -0.860% -6.547% -4.579% 53.010% -18.847% -61.859% -56.182%
Transgene S.A. 1.730% 13.934% 23.886% -33.333% 3.731% -46.947% -52.801%

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-11-01

Boasting a notable position in the Biotechnology & Medical Research sector, Cellectis, traded under the US symbol, is a company whose financial status merits careful analysis. At first glance, it stands out that the company's financial health is dotted with a mix of promising signs and areas worthy of concern.

On the promising front, the firm's total assets increased to $469,471,000 in 2020 compared to $382,076,000 in 2021, signalling a strong asset base. Despite the subsequent drop in 2022 to $261,216,000, the overall trend shows substantial financial growth. The company’s cash and short-term investments followed a similar pattern, reaching a high of $268,239,000 in 2020.

Moreover, the total revenue of Cellectis also witnessed growth, registering a figure of $73,949,000 in 2020, and growing to $191,710,000 in 2022. The enormous figures for total current assets and gross profit margins, as well as a high EPS (Earnings Per Share), adds an appealing touch to the financial attractiveness of Cellectis.


Buy Cellectis Nom.
Show more